Editas Medicine Inc (EDIT) CEO Katrine Bosley Sells 12,000 Shares
Editas Medicine Inc (NASDAQ:EDIT) CEO Katrine Bosley sold 12,000 shares of the company’s stock in a transaction dated Tuesday, January 8th. The stock was sold at an average price of $25.27, for a total value of $303,240.00. Following the completion of the sale, the chief executive officer now owns 1,204,966 shares in the company, valued at approximately $30,449,490.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Katrine Bosley also recently made the following trade(s):
- On Monday, December 3rd, Katrine Bosley sold 12,000 shares of Editas Medicine stock. The stock was sold at an average price of $31.92, for a total value of $383,040.00.
- On Thursday, November 1st, Katrine Bosley sold 12,000 shares of Editas Medicine stock. The stock was sold at an average price of $26.88, for a total value of $322,560.00.
Shares of Editas Medicine stock opened at $26.41 on Friday. Editas Medicine Inc has a 12 month low of $17.80 and a 12 month high of $45.02. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -8.86 and a beta of 3.07. The company has a quick ratio of 13.13, a current ratio of 13.14 and a debt-to-equity ratio of 0.15.
Several institutional investors have recently made changes to their positions in EDIT. ARK Investment Management LLC raised its holdings in shares of Editas Medicine by 28.1% during the third quarter. ARK Investment Management LLC now owns 2,793,854 shares of the company’s stock valued at $88,900,000 after acquiring an additional 612,282 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Editas Medicine by 20.7% during the second quarter. BlackRock Inc. now owns 3,455,066 shares of the company’s stock valued at $123,796,000 after acquiring an additional 591,442 shares during the last quarter. Valiant Capital Management L.P. acquired a new position in shares of Editas Medicine during the third quarter valued at approximately $12,085,000. Renaissance Technologies LLC acquired a new position in shares of Editas Medicine during the third quarter valued at approximately $9,549,000. Finally, Credit Suisse AG increased its holdings in shares of Editas Medicine by 40.9% in the third quarter. Credit Suisse AG now owns 783,088 shares of the company’s stock valued at $24,918,000 after purchasing an additional 227,266 shares during the last quarter. 68.76% of the stock is owned by institutional investors and hedge funds.
EDIT has been the topic of a number of recent research reports. BidaskClub upgraded Editas Medicine from a “hold” rating to a “buy” rating in a research note on Thursday, September 13th. Zacks Investment Research upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $32.00 target price on the stock in a research note on Tuesday, November 13th. SunTrust Banks reaffirmed a “buy” rating on shares of Editas Medicine in a report on Monday, December 31st. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Editas Medicine in a report on Thursday. Finally, ValuEngine cut Editas Medicine from a “buy” rating to a “hold” rating in a report on Friday, December 21st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $45.50.
TRADEMARK VIOLATION WARNING: “Editas Medicine Inc (EDIT) CEO Katrine Bosley Sells 12,000 Shares” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://theolympiareport.com/2019/01/11/editas-medicine-inc-edit-ceo-katrine-bosley-sells-12000-shares-2.html.
About Editas Medicine
Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.
Featured Article: Consumer Price Index (CPI)
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.